Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors.

[1]  Thangavel Arunachalam,et al.  177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  M. Zalutsky,et al.  Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  E. Klein.  Selenium and Vitamin E Cancer Prevention Trial , 2004, Annals of the New York Academy of Sciences.

[4]  J. Reubi,et al.  Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors , 2004, Cancer Research.

[5]  R. Sinha,et al.  Mechanisms of mammary cancer chemoprevention by organoselenium compounds. , 2004, Mutation research.

[6]  M. Vazquez,et al.  Selenomethionine protects against adverse biological effects induced by space radiation. , 2004, Free radical biology & medicine.

[7]  T. Hoffman,et al.  Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. , 2003, Nuclear medicine and biology.

[8]  Shuang Liu,et al.  Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. , 2003, Bioconjugate chemistry.

[9]  T. Visser,et al.  The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  J. Hunter,et al.  Inhibition of ultraviolet B radiation‐induced interleukin 10 expression in murine keratinocytes by selenium compounds , 2002, The British journal of dermatology.

[11]  D. Edwards,et al.  Stabilization of 90Y-Labeled DOTA-Biomolecule Conjugates Using Gentisic Acid and Ascorbic Acid , 2001 .

[12]  S. Jurisson,et al.  Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. , 2001, Nuclear medicine and biology.

[13]  S. Jurisson,et al.  Current and potential therapeutic uses of lanthanide radioisotopes. , 2000, Cancer biotherapy & radiopharmaceuticals.

[14]  G. Schrauzer.  Selenomethionine: a review of its nutritional significance, metabolism and toxicity. , 2000, The Journal of nutrition.

[15]  J. Weiss,et al.  Radioprotection by selenium compounds , 1992, Biological Trace Element Research.

[16]  W. Garrison.  REACTION MECHANISMS IN THE RADIOLYSIS OF PEPTIDES, POLYPEPTIDES AND PROTEINS II REACTIONS AT SIDE-CHAIN LOCI IN MODEL SYSTEMS , 1982 .

[17]  S. Lipsky,et al.  Mechanisms of Protection in Radiolysis of Organic Systems , 1957 .

[18]  M. Macka,et al.  Separation of dithiocarbamate metal complexes by micellar electrokinetic chromatography , 1998 .

[19]  J. Weiss,et al.  Radioprotection by misoprostol (PGE1 methyl analog) in combination with vitamin E, selenomethionine and WR-3689794. , 1997, Advances in experimental medicine and biology.

[20]  G. Colombetti,et al.  E.P.R. OF RADIATION-INDUCED RADICALS IN SULFUR- AND SELENIUM-AMINO ACIDS. , 1972 .

[21]  G. Colombetti,et al.  E.P.R. of radiation-induced radicals in A- and Se-amino acids. , 1972, International journal of radiation biology and related studies in physics, chemistry, and medicine.